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L iver biopsy continues to be an integral part in the diagnosis and management o f many liver diseases.1 In the case o f hepatitis C, liver biopsy is very useful in determining prognosis, which reflects significantly on the decision to prescribe effective cur rent antiviral therapy. Because liver biopsy is costly2 and not without risk, many studies have been performed to evaluate the use o f readily available laboratory test results to predict significant fibrosis or cirrhosis in pa tients with chronic hepatitis C.3 These tests have either been simple, readily available laboratory tests such as transaminases and the platelet count4-6 or more ad vanced, not widely available serum markers o f fibrosis, like the Fibrotest7 and other liver matrix constituents and mediators o f matrix remodeling. 8, 9 In this study we reviewed all liver biopsies per formed for patients with chronic hepatitis C in our unit at a large university hospital in Saudi Arabia in an attempt to validate the clinical utility o f the platelet count, A S T / ALT ratio, and the A ST to APRI score in predicting the presence or absence o f advanced fibrosis and cirrhosis in patients with chronic hepatitis C.
M ETHODS
Liver biopsy procedures performed in our gastroenter ology unit at King Khalid University Hospital, Riyadh, Saudi Arabia were traced from records between the years 1998 to 2003. Histopathology reports were ob tained on all patients. In our unit, liver biopsy is per formed in patients with chronic viral hepatitis if they have (1) elevated liver enzymes, (2) a detectable virus in the blood by a sensitive polymerase chain reaction (PCR) test, and (3) when there are no contraindica tions for antiviral therapy. The liver biopsies in these cases were performed routinely before initiation o f an tiviral therapy. Only a minority o f the patients in this cohort underwent liver biopsy despite normal liver enzymes because o f other reasons, mainly suspicion o f early cirrhosis. Patients were excluded from the study if the biopsy specimen was considered inadequate by the pathologist, if the clinical data on the patient was missing, if the patient was on antiviral therapy, if the patients had hepatitis B and C co-infection, if the pa tient had hepatitis D co-infection, or if the patient was on hemodialysis.
Histological assessment was performed by three experienced liver pathologists who were not blinded to the basic clinical data o f the patients. The following histological parameters were collected: overall liver ar chitecture, portal tract inflammation, interface hepati tis, cholestasis, bile duct injury, liver cell abnormalities, presence o f steatosis, grade o f inflammation, and stage o f fibrosis according to the METAVIR liver histology classification system.10 Advanced fibrosis was defined as a fibrosis stage o f 3 or 4. We were unable to collect data regarding the size o f the biopsy and the number o f fragments obtained because o f the retrospective nature o f the study, but all reported biopsies were considered adequate by the reporting pathologist and all contained more than 4 portal tracts. The hospital computer database was then accessed and the following laboratory data were collected on each patient: W BC count, hemoglobin, mean corpus cular volume (M C V ), platelet count, total bilirubin, albumin, alkaline phosphatase (ALP), ALT, AST, gamma-glutamyl-transferase (G G T) and viral hepatitis serology. Forty-five U /L was considered the upper limit o f normal for ALT and AST. The APRI score was cal culated by dividing the A ST level by 45 (upper limit o f normal) and then multiplying it by 100, and then divid ing the total in the platelet count, as described by the original article by Wai.19 The data was entered in MS Excel software. SPSS PC+ statistical software was used for the statisti cal analysis. The association between the categorical variables was assessed by using the chi-square test or Fisher exact test. The sensitivity, specificity, positive and negative predictive values were calculated to assess the valuables (platelet count, A ST /A L T ratio, and the APRI score) in the prediction o f the presence or ab sence o f advanced fibrosis and cirrhosis in patients with hepatitis C. The receiver operating characteristic curves (RO C) were drawn to find the optimum cut-off points that have high sensitivity and specificity. The area un der the curve (AUC) was calculated with its 95% con fidence intervals.
RESULTS
Two hundred and seventy-nine liver biopsies were identified. O f these, 13 were excluded from the analysis (9 because o f inadequate biopsy size and 4 because o f missing laboratory data). Twenty patients were further excluded because they were on antiviral therapy, had hepatitis B and C co-infection, or were on hemodialy sis.
The baseline characteristics o f the 246 included pa tients are shown in Tables 1 and 2 . The mean age o f the patients was 45 years and about 60% were males. The mean ALT was 112. Most patients had either grade 2 or 3 inflammation (78%), while only a minority had grades 1 or 4. On the other hand, biposies from the majority o f patients had stage 1 (28%) and stage 2 (40%) fibrosis, while only about 26% had advanced fibrosis ( Table 2) .
For predicting advanced fibrosis, the platelet count was applied as a predictive variable and it was found from the ROC curve that the AUC was 0.783, while with the A S T /A L T ratio the AUC was 0.716 ( Figure  1 ). For platelet count we tried using 120 and 100 as cut-offs to predict the presence or absence o f advanced fibrosis, while we used >0.65 and 0.70 as cut-offs for the A S T /A L T ratio ( Table 3) .
The APRI score yielded the highest AUC (0.812). We were not able to find a single APRI score cut-off value to predict the presence or absence o f advanced fibrosis, but rather we found that two cut-off points were best used (Table 3) . A cut-off point o f more than 1.5 would correctly predict the presence o f advanced fi brosis with 90% specificity and 32% sensitivity. On the other hand, a cut-off value o f less than 0.50 would pre dict the absence o f advanced fibrosis with a sensitivity o f 87% and a specificity o f 59%. Reviewing the literature, we found that the three simple laboratory tests that have been well investigated and found to be useful in patients with chronic hepatitis C: are the platelet count,13-15 the A S T /A L T ratio,16-18 and the APRI score. 19 In our study, we attempted to validate these scores in our patients in Saudi Arabia. This was based on the fact that there are potential differences between our pa tients in Saudi Arabia and the patients on which these tests were initially developed and subsequently validat ed. These factors include the difference in age and mode o f virus acquisition, a lower frequency o f alcohol con sumption in the Saudi population, and the prevalence o f other non-cirrhotic causes o f portal hypertension in Saudi Arabia, especially schistosomiasis, which may af fect the fibrosis progression.
In patients with hepatitis C, when the three abovementioned predictors were compared, the APRI score was the one associated with the highest AUC, 0. cutoff value o f the APRI score was >1.50, this is as sociated with a high specificity o f >90% and sensitivity o f 30% in predicting advanced fibrosis (Table 3) . These results are quite comparable to the results reported by Wai in which the AUC o f APRI for predicting signifi cant fibrosis and cirrhosis were 0.80 and 0.89, respec tively,19 and to the more recently reported prospective validation by Castera.7 Our study suffers from some o f the inherent weak nesses o f any retrospective analyses. We were unable to collect information on the size o f the biopsy and number o f fragments. Recently, Bedossa and others have shown that there is a wide sampling variability in assessment o f fibrosis in liver biopsy most o f which is related to the size o f the biopsy.20
In Saudi Arabian patients with chronic hepatitis C, while a low platelet count and a high A ST/A LT ratio were good predictors o f advanced fibrosis, the APRI score seems to be more precise in predicting the presence or absence o f advanced fibrosis. The validation o f the utility o f these simple laboratory predictive factors o f ad vanced fibrosis and cirrhosis in a population different in many ways from the population on which it was initially developed proves the universal utility o f these factors.
